Načítá se...
Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
Isocitrate dehydrogenase 2 (IDH2), an important mitochondrial metabolic enzyme involved in the tricarboxylic acid cycle, is mutated in a variety of cancers. AG‐221, an inhibitor primarily targeting the IDH2‐R140Q mutant, has shown remarkable clinical benefits in the treatment of relapsed or refracto...
Uloženo v:
| Vydáno v: | Cancer Sci |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6778631/ https://ncbi.nlm.nih.gov/pubmed/31361380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14152 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|